CAMP
Income statement / Annual
Last year (2024), CAMP4 Therapeutics Corporation's total revenue was $186.23 M,
a decrease of 36.86% from the previous year.
In 2024, CAMP4 Therapeutics Corporation's net income was -$93.26 M.
See CAMP4 Therapeutics Corporation’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
11/30/2023 |
02/28/2023 |
02/28/2022 |
02/28/2021 |
02/29/2020 |
02/28/2019 |
02/28/2018 |
02/28/2017 |
02/29/2016 |
02/28/2015 |
| Operating Revenue |
$186.23 M
|
$294.95 M
|
$295.84 M
|
$308.59 M
|
$366.11 M
|
$363.80 M
|
$365.91 M
|
$351.10 M
|
$280.72 M
|
$250.61 M
|
| Cost of Revenue |
$119.25 M |
$185.94 M |
$173.95 M |
$186.18 M |
$222.80 M |
$216.04 M |
$215.02 M |
$207.75 M |
$177.76 M |
$163.20 M |
| Gross Profit |
$66.98 M |
$109.01 M |
$121.89 M |
$122.41 M |
$143.30 M |
$147.76 M |
$150.89 M |
$143.35 M |
$102.96 M |
$87.40 M |
| Gross Profit Ratio |
0.36 |
0.37 |
0.41 |
0.4 |
0.39 |
0.41 |
0.41 |
0.41 |
0.37 |
0.35 |
| Research and Development
Expenses |
$14.69 M
|
$24.57 M
|
$28.44 M
|
$25.81 M
|
$29.44 M
|
$27.66 M
|
$25.76 M
|
$22.01 M
|
$19.80 M
|
$19.85 M
|
| General & Administrative
Expenses |
$31.48 M
|
$51.82 M
|
$52.33 M
|
$49.08 M
|
$57.67 M
|
$31.07 M
|
$52.09 M
|
$55.90 M
|
$25.07 M
|
$15.58 M
|
| Selling & Marketing
Expenses |
$29.53 M
|
$47.39 M
|
$48.56 M
|
$46.20 M
|
$60.53 M
|
$49.89 M
|
$50.10 M
|
$49.04 M
|
$23.38 M
|
$20.44 M
|
| Selling, General &
Administrative Expenses |
$61.01 M
|
$99.21 M
|
$100.90 M
|
$95.28 M
|
$118.20 M
|
$80.96 M
|
$102.19 M
|
$104.95 M
|
$48.45 M
|
$36.02 M
|
| Other Expenses |
$0.00 |
$5.33 M |
$5.42 M |
$4.78 M |
$12.32 M |
-$672,000.00 |
$445,000.00 |
-$101,000.00 |
-$20,000.00 |
-$68,000.00 |
| Operating Expenses |
$75.70 M |
$129.11 M |
$134.76 M |
$125.87 M |
$159.96 M |
$120.05 M |
$142.94 M |
$142.01 M |
$74.87 M |
$62.46 M |
| Cost And Expenses |
$194.95 M |
$315.05 M |
$308.71 M |
$312.05 M |
$382.76 M |
$336.09 M |
$357.96 M |
$349.76 M |
$252.63 M |
$225.67 M |
| Interest Income |
$2.81 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$6.26 M |
$15.32 M |
$15.49 M |
$20.10 M |
$16.73 M |
$10.28 M |
$9.90 M |
$7.60 M |
$72,000.00 |
| Depreciation &
Amortization |
$0.00
|
$21.76 M
|
$22.80 M
|
$22.00 M
|
$31.99 M
|
$20.02 M
|
$22.96 M
|
$23.47 M
|
$10.21 M
|
$9.39 M
|
| EBITDA |
-$8.72 M
|
$276,000.00
|
$7.49 M
|
$18.13 M
|
$15.22 M
|
$47.05 M
|
$31.36 M
|
$24.71 M
|
$38.27 M
|
$34.33 M
|
| EBITDA Ratio |
-0.05 |
0 |
0.03 |
0.06 |
0.04 |
0.13 |
0.09 |
0.07 |
0.14 |
0.14 |
| Operating Income Ratio
|
-0.05
|
-0.07
|
-0.05
|
-0.01
|
-0.05
|
0.05
|
0.02
|
0
|
0.1
|
0.1
|
| Total Other
Income/Expenses Net |
-$84.02 M
|
-$9.86 M
|
-$14.75 M
|
-$16.73 M
|
-$41.55 M
|
$12.87 M
|
$31.03 M
|
$1.59 M
|
$1.85 M
|
-$140,000.00
|
| Income Before Tax |
-$92.74 M |
-$31.34 M |
-$30.06 M |
-$20.60 M |
-$58.32 M |
$23.86 M |
$28.71 M |
-$6.97 M |
$22.34 M |
$24.80 M |
| Income Before Tax Ratio
|
-0.5
|
-0.11
|
-0.1
|
-0.07
|
-0.16
|
0.07
|
0.08
|
-0.02
|
0.08
|
0.1
|
| Income Tax Expense |
-$525,000.00 |
$1.15 M |
$1.09 M |
$561,000.00 |
$20.45 M |
-$1.33 M |
$10.68 M |
-$1.10 M |
$4.57 M |
$8.29 M |
| Net Income |
-$93.26 M |
-$32.49 M |
-$31.15 M |
-$21.16 M |
-$78.77 M |
$18.40 M |
$16.62 M |
-$7.15 M |
$16.94 M |
$16.51 M |
| Net Income Ratio |
-0.5 |
-0.11 |
-0.11 |
-0.07 |
-0.22 |
0.05 |
0.05 |
-0.02 |
0.06 |
0.07 |
| EPS |
-2.52 |
-0.9 |
-0.88 |
-0.62 |
-2.34 |
0.53 |
0.47 |
-0.2 |
0.46 |
0.46 |
| EPS Diluted |
-2.52 |
-0.9 |
-0.88 |
-0.62 |
-2.34 |
0.52 |
0.46 |
-0.2 |
0.46 |
0.45 |
| Weighted Average Shares
Out |
$37.02 M
|
$36.10 M
|
$35.25 M
|
$34.12 M
|
$33.48 M
|
$34.59 M
|
$35.25 M
|
$35.92 M
|
$36.45 M
|
$35.78 M
|
| Weighted Average Shares
Out Diluted |
$37.02 M
|
$36.13 M
|
$35.25 M
|
$34.39 M
|
$33.67 M
|
$35.29 M
|
$36.14 M
|
$35.92 M
|
$36.95 M
|
$36.53 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
